a hormone that controls red blood cell production. Produced by the liver and the kidney erythropoietin activates the red blood cell precursors in the bone marrow to begin producing red blood cells. It also increases red blood cell survival rates and plays an important role in healing damaged neurons in the brain.
Erythropoietin has been used to treat anemia in cancer, kidney disease and other diseases. Erythorpoietin recently improved fatigue and quality of life in seniors with anemia. The first erythropoietin agent, Epogen , was FDA approved in 1989. Two brands of erythropoietin, epoetin (Procrit) and darbepoietin (Aranesp)
Recent clinical trials indicating erythropoietin had little benefit in cancer patients and may increase the risk of several cancers resulted in the FDA giving it a ‘black box’ warning. In high doses erythropoietin also increases the risk of cardiovascular events. In general erythropoietin is given at the smallest possible dose needed to produce an effect.
Because it increases red blood cell levels – which in turn deliver oxygen to the muscles – erythropoietin has been used as a performance enhancing drug in athletics. It use is banned in cycling and other sports.
Erythropoietin May Work in Chronic Fatigue Syndrome (ME/CFS) Because…
it increases red blood cell mass and thus may help increase blood volume in a prominent subset of patients. Low blood volume may contribute to orthostatic intolerance (symptoms when standing), low blood flows to the brain and other organs and low energy in ME/CFS.
Chronic Fatigue Syndrome (ME/CFS) Studies
At the 2007 IACFS/ME conference Dr. Hurwitz reported that an NIH sponsored trial of erythropoietin did increase blood volume in ME/CFS patients but did not result in significant health benefits. This is the second trial of a blood volume enhancer that succeeded in its first purpose – increasing blood volume- but failed at its second – improving patients health. This suggests low blood volume is a secondary component of CFS.
At the same conference, however, Dr. Shoemaker reported that higher doses of the drug reduced levels of the complement protein C4a, normalized lactate levels in the hippocampus and improved patients health and cognitive functioning. Neither his study (which had no control group, etc.) nor Dr. Hurwitz’s s have been published.
Used at levels that produce high red blood cell levels erythropoietin can increase the risk of cardiovascular events such as blood clots, heart attacks and stroke. Erythropoietin may increase the risk of several cancers.
Mayo Clinic Erthyropoietin drugs: what to know about anemia fighting medications. https://www.mayoclinic.com/health/erythropoietin/DA00137
Cort Johnson, The Phoenix Rising Guide to the 8th IACFS Conference, Jan 2007
Part IV: The Clinical Trials
Anemia drugs increase death risk. https://foodconsumer.org/7777/8888/Non-f_ood_Things_27/030912112007_Anemia_drugs_increase_death_risk_printer.shtml